Pharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 30,712 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 30,712 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director directly owned 315,167 shares of the company’s stock, valued at $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The stock was sold at an average price of $35.05, for a total transaction of $241,424.40.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The shares were sold at an average price of $30.07, for a total value of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Trading Down 1.8%

Shares of PHVS opened at $33.95 on Thursday. The stock has a market cap of $2.22 billion, a PE ratio of -10.68 and a beta of -2.34. Pharvaris N.V. has a 1 year low of $17.05 and a 1 year high of $35.90. The stock has a 50 day simple moving average of $30.90 and a 200-day simple moving average of $28.21.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, sell-side analysts forecast that Pharvaris N.V. will post -3.2 EPS for the current fiscal year.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed its Buy rating on Pharvaris, which can support investor confidence in the company’s longer-term outlook. Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
• Positive Sentiment: PHVS recently reached a new 1-year high, suggesting momentum has been strong heading into today’s trading. Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Still a Buy?
• Neutral Sentiment: The company’s insider activity included multiple sales by Anne Lesage and Director Johannes Gerardus Chri Schikan on June 29-30, totaling a sizable reduction in their holdings. While insider sales do not always signal a fundamental problem, they can weigh on sentiment because investors may view them as a sign of limited near-term upside. SEC insider filing

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PHVS shares. UBS Group set a $74.00 target price on shares of Pharvaris in a research report on Wednesday, May 13th. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Morgan Stanley lifted their target price on shares of Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.64.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL bought a new stake in shares of Pharvaris during the third quarter worth approximately $1,943,000. Integral Health Asset Management LLC acquired a new stake in Pharvaris during the 3rd quarter worth $4,990,000. PSP Research LLC bought a new stake in shares of Pharvaris during the 4th quarter valued at $569,000. JPMorgan Chase & Co. raised its position in shares of Pharvaris by 710.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after acquiring an additional 23,743 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its stake in shares of Pharvaris by 735.1% in the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock valued at $3,373,000 after purchasing an additional 118,994 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.